AB
Altesa BioSciences
United States · Biotech
Clinical-stage developer of oral antiviral medicines for people with chronic lung disease.
Targeting viral triggers of respiratory attacks
Altesa BioSciences develops medicines intended to reduce the harm caused by respiratory virus infections in people with chronic lung diseases, including COPD and asthma. Its lead programme, vapendavir, is an oral antiviral directed at rhinovirus, a trigger of acute respiratory exacerbations.
The company holds exclusive worldwide rights to develop, manufacture and commercialize vapendavir. Its work centres on clinical development: evaluating the medicine in people with COPD and rhinovirus infection and building the evidence needed for a potential treatment.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series B | $75M | Atlantic Partners — Role not disclosedForbion — Role not disclosedMedicxi — Role not disclosedPitango — Role not disclosedSanofi — Role not disclosed |